ImmPORT Therapeutics, Inc 1 Technology Dr # E309 Category: Wholesale Pharmaceutical Products
|
 |
Company representatives
Xiaowu Liang, President & CEO
About ImmPORT Therapeutics, Inc
Discovery of biomarkers using high throughput proteomics tools for the development of diagnostics, therapeutics and vaccines.
Antigen Discovery Inc.'s (ADi, formerly ImmPORT Therapeutics Inc. ) technology platform alleviates the major bottleneck that currently limits the transformation of genomic information into next generation medical advancements.
ADi’s high throughput technology surveys mammalian immune responses in a fast and comprehensive manner. The methods rapidly identify novel biomarkers, vaccine targets, and therapeutic protein candidates from infectious organisms, auto-immune disease states, and cancers.
Products and Services
- Biomarker Discovery
- Diagnostics
Location Type
Single Location
Revenue
$3,500,000 - $3,750,000
Employees
10 to 19
Years In Business
20
Rating
Browse U.S. states for Wholesale Pharmaceutical Products
